Choroid plexus alterations in long COVID and their associations with Alzheimer's disease risks
Alzheimer's & Dementia · 2026-02 · 22 (2)
DOI: 10.1002/alz.71020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 30.01.2026. Verfasst von Huize Pang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, NYU Grossman School of Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Choroid Plexus, Alzheimer Disease, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The National Institutes of Health/National Institute on Aging, NIH HHS, NINDS NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Choroid plexus (ChP) enlargement is a neuroimaging biomarker of neuroinflammation and neurodegeneration. However, evidence of ChP structural and perfusion alterations in long coronavirus disease (COVID) and their clinical relevance remains limited. METHODS This study included 86 long COVID, 67 recovered COVID, and 26 COVID‐negative healthy controls (HCs). ChP volume and cerebral blood flow (CBF) were quantified, and their associations with Alzheimer's disease (AD) symptoms and plasma biomarkers were examined. RESULTS Both patient groups showed higher ChP volume and lower CBF than HC. Relative to recovered COVID, long COVID patients had a larger ChP volume, but no significant difference in CBF. ChP volume correlated positively with glial fibrillary acidic protein ( r = 0.35) and phosphorylated tau217 (p‐tau217; r = 0.54), while CBF correlated negatively with p‐tau217 ( r = –0.56). Both ChP volume and CBF were associated with cognitive decline measured with Mini‐Mental State Examination and Clinical Dementia Rating. DISCUSSION These findings suggest that ChP differences in long COVID are associated with AD‐related cognitive decline and increased plasma biomarkers. Highlights Long coronavirus disease (COVID) patients show choroid plexus (ChP) enlargement and reduced cerebral blood flow. ChP alterations are associated with Alzheimer's disease (AD)‐related symptoms and plasma biomarker changes. ChP alterations on magnetic resonance imaging may serve as imaging markers for tracking neurological symptoms and AD‐related pathology in post‐COVID patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, NYU Grossman School of Medicine, New York, New York, USA.
- Department of Neurology, NYU Grossman School of Medicine, New York, New York, USA.
ORCID-Profile: Yulin Ge
Förderung
- The National Institutes of Health/National Institute on Aging
- NIH HHS
- NINDS NIH HHS
- NIA NIH HHS
- National Institutes of Health
Zitieren
APA
Pang, H., Frontera, J., Jiang, L., Li, C., Boutajangout, A., Sun, Z., Debure, L., Ghuman, M., Vedvyas, A., Masurkar, A. V., Wisniewski, T., & Ge, Y. (2026). Choroid plexus alterations in long COVID and their associations with Alzheimer's disease risks. Alzheimer's & Dementia, 22(2). https://doi.org/10.1002/alz.71020
Vancouver
Pang H, Frontera J, Jiang L, Li C, Boutajangout A, Sun Z, et al. Choroid plexus alterations in long COVID and their associations with Alzheimer's disease risks. Alzheimer's & Dementia. 2026;22(2). doi:10.1002/alz.71020
BibTeX
@article{Pang2026,
author = {Pang, Huize and Frontera, Jennifer and Jiang, Li and Li, Chenyang and Boutajangout, Allal and Sun, Zhe and Debure, Ludovic and Ghuman, Mobeena and Vedvyas, Alok and Masurkar, Arjun V and Wisniewski, Thomas and Ge, Yulin},
title = {Choroid plexus alterations in long COVID and their associations with Alzheimer's disease risks},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {2},
doi = {10.1002/alz.71020}
}
EUVIMED